RLAY in the 13F filings
Relay Therapeutics Inc · CUSIP 75943R102
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 25
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 1 listed it in both
- Shares listed
- 27,887,171
- combined, among listed positions
- Reported value
- $236m
- combined, at the quarter end
Among the 92 comparable managers: 14 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,585,936.
Managers listing RLAY in Q4 2025
25 of 25 holders
Largest increases and reductions, by shares
Increases
- ExodusPoint Capital Management LPnew position · 1,141,880 shares now+1,141,880
- Balyasny Asset Management LLCexisting position · 2,099,912 shares now+924,941
- T. Rowe Price Associates Incexisting position · 1,645,403 shares now+507,722
- Invesco Ltdexisting position · 865,481 shares now+504,291
- Two Sigma Investments LPexisting position · 1,560,265 shares now+464,630
Reductions
- Point72 Asset Management LPexisting position · 13,859,172 shares now-914,504
- Renaissance Technologies LLCexisting position · 647,899 shares now-375,211
- Woodline Partners LPexisting position · 679,115 shares now-339,000
- AQR Capital Management LLCexisting position · 1,163,124 shares now-137,912
- Jane Street Group LLCexisting position · 76,476 shares now-108,475
New positions and exits
New (6)
Exited (1)
- Brevan Howard Capital Management LPwas $322k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2020 | 2 | $57m | n.a. | n.a. |
| Q4 2020 | 4 | $23m | n.a. | n.a. |
| Q1 2021 | 3 | $21m | n.a. | n.a. |
| Q2 2021 | 2 | $18m | n.a. | n.a. |
| Q3 2021 | 4 | $449m | n.a. | n.a. |
| Q4 2021 | 4 | $515m | n.a. | n.a. |
| Q1 2022 | 5 | $514m | n.a. | n.a. |
| Q2 2022 | 4 | $16m | n.a. | n.a. |
| Q3 2022 | 7 | $131m | n.a. | n.a. |
| Q4 2022 | 3 | $16m | n.a. | n.a. |
| Q1 2023 | 4 | $129m | n.a. | n.a. |
| Q2 2023 | 3 | $8.6m | n.a. | n.a. |
| Q3 2023 | 4 | $6.9m | n.a. | n.a. |
| Q4 2023 | 4 | $12m | 2 | 1 |
| Q1 2024 | 4 | $7.6m | 1 | 3 |
| Q2 2024 | 4 | $5.8m | 2 | 2 |
| Q3 2024 | 2 | $2.9m | 1 | 2 |
| Q4 2024 | 1 | $447k | 0 | 1 |
| Q1 2025 | 1 | $28m | 1 | 0 |
| Q2 2025 | 1 | $47m | 1 | 0 |
| Q3 2025 | 1 | $77m | 1 | 0 |
| Q4 2025 | 3 | $127m | 14 | 10 |
| Q2 2026 | 2 | $25m | 14 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RLAY and GILD →RLAY and AMGN →RLAY and ARGX →Choose a stock to compare with RLAY →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RLAY, latest filings →Back to the 13F Explorer →